| Company name | Ticker | Asset type | Sector | Market cap | % in ETF |
|---|---|---|---|---|---|
| TWST | Stock | Healthcare | US$ 12.51 B | 9,86% | |
| TEM | Stock | Healthcare | US$ 13.83 B | 8,88% | |
| TXG | Stock | Healthcare | US$ 12.18 B | 8,05% | |
| ABSI | Stock | Healthcare | US$ 1.90 B | 5,26% | |
| CRSP | Stock | Healthcare | US$ 5.36 B | 5,16% | |
| NTRA | Stock | Healthcare | US$ 59.15 B | 4,99% | |
| ILMN | Stock | Healthcare | US$ 41.23 B | 4,92% | |
| CDNA | Stock | Healthcare | US$ 3.47 B | 4,91% | |
| PSNL | Stock | Healthcare | US$ 1.74 B | 4,36% | |
| LLY | Stock | Healthcare | US$ 1.02 T | 3,86% | |
| GH | Stock | Healthcare | US$ 23.86 B | 3,10% | |
| BEAM | Stock | Healthcare | US$ 2.53 B | 2,96% | |
| SDGR | Stock | Healthcare | US$ 2.27 B | 2,88% | |
| CMPS | Stock | Healthcare | US$ 1.65 B | 2,82% | |
| NTLA | Stock | Healthcare | US$ 1.72 B | 2,82% | |
| RXRX | Stock | Healthcare | US$ 2.21 B | 2,79% | |
| VCYT | Stock | Healthcare | US$ 3.68 B | 2,33% | |
| BFLY | Stock | Healthcare | US$ 2.38 B | 2,20% | |
| NRIX | Stock | Healthcare | US$ 2.39 B | 2,12% | |
| ADPT | Stock | Healthcare | US$ 4.52 B | 1,90% | |
| WGS | Stock | Healthcare | US$ 2.18 B | 1,74% | |
| IONS | Stock | Healthcare | US$ 7.24 B | 1,72% | |
| ARCT | Stock | Healthcare | US$ 370.35 M | 1,69% | |
|
Alamar Biosciences, Inc. Common Stock
|
ALMR | Stock | Healthcare | US$ 2.38 B | 1,58% |
| PACB | Stock | Healthcare | US$ 789.51 M | 1,38% | |
| MASS | Stock | Healthcare | US$ 524.52 M | 1,25% | |
| PRME | Stock | Healthcare | US$ 540.50 M | 1,07% | |
|
Generate Biomedicines, Inc. Common Stock
|
GENB | Stock | Healthcare | US$ 1.76 B | 0,97% |
| CERS | Stock | Healthcare | US$ 459.48 M | 0,83% | |
|
Scribe Therapeutics Inc. Common Stock
|
SCTX | Stock | Healthcare | US$ 317.86 M | 0,58% |
| FRNM | Stock | Healthcare | US$ 1.75 B | 0,54% | |
| QSI | Stock | Healthcare | US$ 339.27 M | 0,46% |
Average Investor10 user rating
4.0
(0 people)
ARK Genomic Revolution UCITS ETF Class A USD Accumulation (Ireland) is an exchange-traded fund (ETF), with assets under management totaling $8.76 million.
Over the past 12 months, ARK Genomic Revolution UCITS ETF Class A USD Accumulation recorded a return of 59.76%, with its price trading between $4.73 and $10.25 during the same period.
The ETF is traded under the ticker ARKG.
The current price of ARKG is $9.49. You can track the real-time price chart, review historical performance, and access detailed information about this ETF on the platform.
ARKG is currently trading at $9.49, with a market capitalization of approximately $8.760.000,00. Over the past year, the ETF has delivered a 59.76% return, based on share price performance.
Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.
You can invest in ARKG through a brokerage account that provides access to the exchange where it is listed. After opening and funding your account, search for the ticker symbol ARKG, select the number of shares you wish to purchase, and place your order.
In certain markets, similar exposure may also be available through locally listed products that track the same index.
Over the past month, ARKG has returned 9.33%, and 59.76% over the past year.
If you were to purchase 100 shares of ARKG at the current price of $9.49, your total investment would be $949.00.
After 1 month the profitability would be $1,037.54.
Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.
Sign in with your social account or email
Create your account
Already have an account? Login
Tesla
Dividend Schedule
Ranking of Stocks
Ranking of Brazilian ETFs
Crypto Rankings
